TC Biopharm intends to launch preclinical study for treatment of Mpox

TC BioPharm announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox, Mpox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T cells which the company expects will have applications in treating the global health emergency. Due to the highly infectious nature of monkeypox, TCBP expects to partner with a leading Infectious Disease Center or University associated with a similar organization to rapidly advance the Proof-of-Concept and pre-clinical studies.